Search COVID-19

Information about the TGA's safety monitoring of COVID-19 vaccines.

The TGA is aware of concerns about decreased effectiveness of monoclonal antibodies against the COVID-19 caused by emerging SAR-COV-2 variants. At this stage, the regulatory status of the products remain unchanged in Australia.

Information about the TGA's safety monitoring of COVID-19 vaccines.

On 17 February, the TGA granted provisional approval to Moderna’s bivalent COVID-19 vaccine. This is the second bivalent vaccine targeting the Omicron BA.4-5 subvariants that has been provisionally approved by the TGA

Information about the TGA's safety monitoring of COVID-19 vaccines.

The TGA has confirmed the performance of COVID-19 rapid antigen tests available on the Australian market with COVID-19 variants.

Information about the TGA's safety monitoring of COVID-19 vaccines.

This is the first vaccine provisionally approved by the TGA that is designed to specifically target the Omicron variants BA.4/BA.5 and follows provisional approval of the Pfizer BA.1 Omicron/original bivalent vaccine.

The TGA has commenced evaluation of an application from Moderna Australia Pty Ltd to transition its COVID-19 vaccine, SPIKEVAX, to full registration for the immunisation of individuals 6 years and over, and as a booster dose for individuals aged 12 years and older.

Information about the TGA's safety monitoring of COVID-19 vaccines.